ClinVar Miner

Submissions for variant NM_000018.4(ACADVL):c.553G>A (p.Gly185Ser) (rs545215807)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000185742 SCV000238670 pathogenic not provided 2016-07-12 criteria provided, single submitter clinical testing The G185S variant has been previously reported in association with very long chain acyl-CoA dehydrogenase (VLCAD) deficiency using an alternative numbering system based on the mature protein (G145S) (Andresen et al., 1999). An individual who was heterozygous for a single G185S mutation in VLCAD was found to have 29% residual VLCAD enzyme activity (Hoffmann et al. 2012).
Invitae RCV000412436 SCV000654958 pathogenic Very long chain acyl-CoA dehydrogenase deficiency 2020-10-10 criteria provided, single submitter clinical testing This sequence change replaces glycine with serine at codon 185 of the ACADVL protein (p.Gly185Ser). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and serine. This variant is present in population databases (rs545215807, ExAC 0.01%). This variant has been reported in combination with other ACADVL variants in the fibroblasts from individuals affected with VLCADD (PMID: 17999356, 20060901, 22841441). ClinVar contains an entry for this variant (Variation ID: 203595). Fibroblasts from affected individuals showed diminished VLCAD protein expression and enzyme activity (PMID: 17999356, 20060901). In addition, fibroblasts from an individual heterozygous of this variant has been shown to have 29% residual enzyme activity (PMID: 21932095). General algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD), and an algorithm developed specifically for the ACADVL gene (PMID: 20060901), suggest that this missense change is likely to be deleterious. However, these predictions have not been confirmed by published functional studies. For these reasons, this variant has been classified as Pathogenic.
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000412436 SCV000883349 pathogenic Very long chain acyl-CoA dehydrogenase deficiency 2020-01-17 criteria provided, single submitter clinical testing The ACADVL c.553G>A, p.Gly185Ser variant (rs545215807), also known as Gly145Ser, has been reported in multiple individuals with very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency (Andresen 1999, Gobin-Limballe 2007, Yamaguchi 2012). Multiple affected individuals with this variant were also found to carry a second pathogenic variant (Gobin-Limballe 2007, Yamaguchi 2012). The p.Gly185Ser variant is listed in ClinVar (Variation ID: 203595) and is observed on only three chromosomes in the Genome Aggregation Database (3/251456 alleles). The glycine at position 185 is highly conserved (Alamut v2.10), and it occurs in the substrate binding cavity of the VLCAD enzyme (Hoffman 2012). Functional characterization of patient fibroblasts carrying this variant indicates a substantial decrease in VLCAD protein levels (Andresen 1999, Gobin-Limballe 2010) and enzymatic activity compared to wildtype (Gobin-Limballe 2007, Hoffman 2012). Based on available information, the p.Gly185Ser variant is considered to be pathogenic. References: Andresen B et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet. 1999; 64(2):479-94. Gobin-Limballe S et al. Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am J Hum Genet. 2007; 81(6):1133-43. Gobin-Limballe S et al. Compared effects of missense mutations in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency: Combined analysis by structural, functional and pharmacological approaches. Biochim Biophys Acta. 2010; 1802(5):478-84. Hoffman L et al. VLCAD enzyme activity determinations in newborns identified by screening: a valuable tool for risk assessment. J Inherit Metab Dis. 2012; 35(2):269-77. Yamaguchi S et al. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay. Mol Genet Metab. 2012; 107(1-2):87-91.
CeGaT Praxis fuer Humangenetik Tuebingen RCV000185742 SCV001246296 pathogenic not provided 2017-05-01 criteria provided, single submitter clinical testing
Wong Mito Lab, Molecular and Human Genetics, Baylor College of Medicine RCV000412436 SCV001364892 pathogenic Very long chain acyl-CoA dehydrogenase deficiency 2019-11-01 criteria provided, single submitter clinical testing The NM_000018.3:c.553G>A (NP_000009.1:p.Gly185Ser) [GRCH38: NC_000017.11:g.7221613G>A] variant in ACADVL gene is interpretated to be Pathogenic based on ACMG guidelines (PMID: 25741868). This variant has been reported in PMID: 9973285. This variant meets the following evidence codes reported in the ACMG guidelines: PS1, PS3
Counsyl RCV000412436 SCV000485276 likely pathogenic Very long chain acyl-CoA dehydrogenase deficiency 2016-10-13 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.